CD37 immunotherapeutics and uses thereof
US10307481B2 · kind B2 · utility
1Cited by
239References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 25, 2006 |
| Grant date | Jun 4, 2019 |
| Priority date | — |
| Expiry date | Aug 16, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.